Characteristics of the patients at baseline
| Characteristics . | Overall, N = 72 . | Standard chemotherapy (COM), n = 32 . | R + standard chemotherapy (R-COM), n = 40 . | P value∗ . |
|---|---|---|---|---|
| Age, median (IQR), y | 9.5 (6.8-12.0) | 8.5 (6.8-12.3) | 10.0 (6.8-12.0) | .9 |
| Sex, n (%) | .8 | |||
| Female | 17 (24) | 8 (25) | 9 (23) | |
| Male | 55 (76) | 24 (75) | 31 (78) | |
| B-symptoms, n (%) | 64 (89) | 27 (84) | 37 (93) | .5 |
| Peripheral LAD, n (%) | 30/57 (53) | 16/26 (62) | 14/31 (45) | .2 |
| Jaw mass, n (%) | 29/65 (45) | 14/27 (52) | 15/38 (39) | .3 |
| Mediastinal mass, n (%) | 2/55 (3.6) | 2/24 (8.3) | 0/31 (0) | .2 |
| Abdominal mass, n (%) | 41/60 (68) | 13/24 (54) | 28/36 (78) | .054 |
| HIV positive, n (%) | 2/52 (3.8) | 1/23 (4.3) | 1/29 (3.4) | >.9 |
| LDH levels, median (IQR), IU/L | 997 (678-1594) | 961 (795-1477) | 1173 (598-1669) | .6 |
| Cytopenias, n (%) | 52/71 (73) | 22/31 (71) | 30/40 (75) | .7 |
| Clinical stage, n (%) | .070 | |||
| Advanced stage | 41 (57) | 22 (69) | 19 (48) | |
| Limited stage | 31 (43) | 10 (3) | 21 (53) |
| Characteristics . | Overall, N = 72 . | Standard chemotherapy (COM), n = 32 . | R + standard chemotherapy (R-COM), n = 40 . | P value∗ . |
|---|---|---|---|---|
| Age, median (IQR), y | 9.5 (6.8-12.0) | 8.5 (6.8-12.3) | 10.0 (6.8-12.0) | .9 |
| Sex, n (%) | .8 | |||
| Female | 17 (24) | 8 (25) | 9 (23) | |
| Male | 55 (76) | 24 (75) | 31 (78) | |
| B-symptoms, n (%) | 64 (89) | 27 (84) | 37 (93) | .5 |
| Peripheral LAD, n (%) | 30/57 (53) | 16/26 (62) | 14/31 (45) | .2 |
| Jaw mass, n (%) | 29/65 (45) | 14/27 (52) | 15/38 (39) | .3 |
| Mediastinal mass, n (%) | 2/55 (3.6) | 2/24 (8.3) | 0/31 (0) | .2 |
| Abdominal mass, n (%) | 41/60 (68) | 13/24 (54) | 28/36 (78) | .054 |
| HIV positive, n (%) | 2/52 (3.8) | 1/23 (4.3) | 1/29 (3.4) | >.9 |
| LDH levels, median (IQR), IU/L | 997 (678-1594) | 961 (795-1477) | 1173 (598-1669) | .6 |
| Cytopenias, n (%) | 52/71 (73) | 22/31 (71) | 30/40 (75) | .7 |
| Clinical stage, n (%) | .070 | |||
| Advanced stage | 41 (57) | 22 (69) | 19 (48) | |
| Limited stage | 31 (43) | 10 (3) | 21 (53) |
LAD, lymphadenopathy; LDH, lactate dehydrogenase; R, rituximab.
Pearson χ2 test; Wilcoxon rank-sum test; Fisher exact test.